Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Monday morning, RTT News reports.

Several other equities research analysts have also recently issued reports on the company. Needham & Company LLC reiterated a buy rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Citigroup lowered their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating on the stock in a report on Friday, February 16th. The Goldman Sachs Group cut Alnylam Pharmaceuticals from a buy rating to a neutral rating and lowered their price objective for the stock from $230.00 to $173.00 in a report on Friday, February 16th. StockNews.com cut Alnylam Pharmaceuticals from a buy rating to a hold rating in a report on Friday. Finally, HC Wainwright reiterated a buy rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Nine analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $216.12.

Alnylam Pharmaceuticals Stock Up 1.6 %

NASDAQ:ALNY opened at $156.04 on Monday. Alnylam Pharmaceuticals has a 52 week low of $143.52 and a 52 week high of $218.88. The stock has a market capitalization of $19.65 billion, a PE ratio of -43.83 and a beta of 0.39. The stock’s 50-day moving average price is $155.84 and its 200-day moving average price is $168.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. During the same quarter last year, the business earned ($1.68) earnings per share. Alnylam Pharmaceuticals’s revenue was up 31.2% on a year-over-year basis. Sell-side analysts expect that Alnylam Pharmaceuticals will post -4.61 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 51 shares during the period. Captrust Financial Advisors boosted its holdings in Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock valued at $187,000 after acquiring an additional 53 shares during the period. Steward Partners Investment Advisory LLC grew its position in Alnylam Pharmaceuticals by 14.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 480 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 60 shares in the last quarter. Bridgewater Associates LP increased its stake in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Bridgewater Associates LP now owns 1,951 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 65 shares during the period. Finally, EP Wealth Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 71 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.